Dublin, Feb. 27, 2018 -- The "Point-of-Care/Rapid Diagnostics Market by Testing (Glucose, Lipids, HbA1c, HCV, HIV, Influenza, Urinalysis, Hematology, Cancer, Pregnancy, PT/INR), Platform (Lateral Flow, Immunoassay), Mode (Prescription, OTC), End-User - Global Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.
The global point-of-care diagnostics market is projected to reach USD 38.13 Billion by 2022 from USD 23.71 Billion in 2017, at a CAGR of 10.0% during the forecast period.
Factors such as high prevalence of infectious diseases in developing countries, increasing incidence of target diseases, and rising preference for home healthcare across the globe are increasing the adoption of POC diagnostic products globally.
This report broadly segments the rapid diagnostic market into product, platform, mode, end user, and region.
The report covers the point-of-care diagnostics market across four major geographies, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to command the largest share of the market in 2017, due to the growing prevalence of lifestyle diseases, increasing number of product approvals, and rising government initiatives in this region.
The major players of the market
- Abbott Laboratories
- Accubiotech
- Becton, Dickinson, and Company (BD)
- Chembio Diagnostics
- Danaher Corporation
- EKF Diagnostics
- Instrumentation Laboratory (A Werfen Company)
- Johnson & Johnson
- Nova Biomedical
- PTS Diagnostics (A Part of Sinocare Inc.)
- Quidel
- Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche Ltd.)
- Sekisui Diagnostics
- Siemens
- Trinity Biotech
Market Dynamics
Drivers
- High Prevalence of Infectious Diseases in Developing Countries
- Increasing Incidence of Target Diseases
- Rising Usage of Home-Based POC Devices
- Growing Government Support
- Technological Advancements and New Product Launches
- Growing Number of Regulatory Approvals for Novel Immunoassay Techniques
- Shortage of Skilled Laboratory Technicians
- Rising Number of Clia-Waived POC Tests
Restraints
- Product Recalls: Hampering User Confidence
- Pricing Pressure Owing to Reimbursement Cuts and Budget Constraints
- Stringent and Time-Consuming Regulatory Policies are Significantly Increasing Gestation Period for Product Launches
Opportunities
- Growth Opportunities in Emerging Markets
- Healthcare Decentralization - Converting Lab Tests to POC Tests
- Increasing Number of Conferences and Events
- POC Tests With Multiplexing Capabilities
Challenges
- Lack of Alignment With Definitive Central Lab Methods
- Inadequate Knowledge About the Use of POC Devices in Professional Settings
- Reluctance Towards Changing Existing Diagnostic Practices
- High Cost of Devices
Emerging Applications of Point-of-Care Testing
- Sepsis Biomarkers
- Stroke Markers
- Thyroid Testing
- Dna Testing
- Endocrine Testing
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Point-of-Care Diagnostics Market, By Product
7 Point-of-Care Diagnostics Market, By Platform
8 Point-of-Care Diagnostics Market, By Prescription Mode
9 Point-of-Care Diagnostics Market, By End User
10 Point-of-Care Diagnostics Market, By Region
11 Competitive Landscape
12 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/s54flj/pointofcarerapi?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Point-of-Care Diagnostics


Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks
DeepSeek to Raise AI API Prices as Demand for New Models Surges 



